Adial Pharmaceuticals, Inc., a biopharmaceutical company based in Glen Allen, Virginia, has filed a Form D Notice of Exempt Offering of Securities with the Securities and Exchange Commission (SEC). The filing, dated March 14, 2024, indicates that the company has successfully raised $287,500 through an equity offering. The offering, which includes options, warrants, or other rights to acquire another security, was made under Rule 506(b) of the Securities Act, exempting it from registration requirements. The first sale of the securities occurred on March 6, 2024, and the offering is not intended to last more than one year. Adial Pharmaceuticals has declined to disclose the issuer size by revenue or aggregate net asset value. The company has also stated that none of the proceeds from the...Show More

Adial Pharmaceuticals, Inc., a biopharmaceutical company based in Glen Allen, Virginia, has filed a Form D Notice of Exempt Offering of Securities with the Securities and Exchange Commission (SEC). The filing, dated March 14, 2024, indicates that the company has successfully raised $287,500 through an equity offering. The offering, which includes options, warrants, or other rights to acquire another security, was made under Rule 506(b) of the Securities Act, exempting it from registration requirements. The first sale of the securities occurred on March 6, 2024, and the offering is not intended to last more than one year. Adial Pharmaceuticals has declined to disclose the issuer size by revenue or aggregate net asset value. The company has also stated that none of the proceeds from the offering will be used to make payments to its executive officers, directors, or promoters. The sole investor in the offering is not an accredited investor, and sales commissions of $23,000 were estimated to be paid to H.C. Wainwright & Co., LLC. The company specializes in the pharmaceuticals sector within the healthcare industry and is incorporated in Delaware.